Oxford, UK – 2nd July 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today the award of an Innovate UK grant to CHAIN Biotechnology Ltd (CHAIN) and the University of Oxford to develop live biotherapeutics that support oral delivery for OVM’s recombinant overlapping peptide (ROP) […]
CHAIN’s drug delivery platform and lead product, β-hydroxybutyrate, is highlighted in a new report ‘Catalysing Investment and Growth’, released by the BioIndustry Association this week. Our microbiome therapeutics are based on spores of Clostridium bacterial species. We have successfully demonstrated scale-up of bacterial spore production with our partners at Porton Biopharma Ltd as part of the Industrial Strategy […]
MARLOW & NOTTINGHAM, UK. — April 8, 2019 – UK microbiome therapeutics company CHAIN Biotechnology has appointed two new non-executive directors, Dr Nel Moore and Dr Robert Haigh to the Board. Dr Nel Moore has considerable experience in drug development with a track record taking therapeutics to market as former Global Product Vice President at […]
Our Clostridium Assisted Drug Development (CADD™) platform provides superior gut delivery to support a pipeline of drug candidates addressing multiple therapeutic areas associated with the gut microbiome.
We target inflammatory bowel disease with a focus on Ulcerative Colitis. Our lead drug candidate is a live biotherapeutic engineered to produce anti-inflammatory metabolites; β-hydroxybutyrate and butyrate.